Metabolism and heart changes in people with worsening heart failure taking vericiguat
Observes metabolism, heart function and blood vessels in adults with worsening heart failure on vericiguat.
Plain-language title generated from the registry record
Registry title: Metabolic Changes in Heart Failure Patients Treated With Vericiguat
Key facts
- Where
- Potenza, ItalySee the site
Where in Italy
- Azienda Ospedaliera Regionale San Carlo di PotenzaPotenza, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Salerno
- Trial code
- NCT07901270
- Record updated
- 29 October 2026
- Original description
Heart failure is a condition in which the heart cannot pump blood as effectively as it should. It can cause symptoms such as shortness of breath, tiredness, and fluid retention. Vericiguat is a medication used in certain patients with heart failure whose symptoms have recently worsened.Read full original descriptionShow less
Metabolic Remodelling in Worsening Heart Failure Treated With Vericiguat: A Prospective Multi-Omics Study Integrating Cardiac Imaging and Endothelial Function
Heart failure is a condition in which the heart cannot pump blood as effectively as it should. It can cause symptoms such as shortness of breath, tiredness, and fluid retention. Vericiguat is a medication used in certain patients with heart failure whose symptoms have recently worsened.
The aim of this study is to better understand how vericiguat treatment is associated with changes in metabolism, heart function, and blood vessel health in patients with heart failure.
This is a prospective, observational study conducted at a single hospital in Italy. Researchers will collect clinical information and analyze biological samples to investigate changes in molecules involved in energy production, inflammation, and cardiovascular function. Heart imaging and assessments of blood vessel function will also be used to better understand the patients' cardiovascular health.
The study will explore whether these biological and cardiovascular measurements are associated with treatment with vericiguat and whether they could help identify patients who may benefit most from this therapy.
The results may improve our understanding of heart failure and support more personalized treatment strategies in the future.
Inclusion: Adults aged 18 years or older; Hospitalized or outpatient patients with worsening heart failure and left ventricular ejection fraction (LVEF) <45%; Patients receiving guideline-directed medical therapy, including an ACE inhibitor or angiotensin receptor-neprilysin inhibitor (ARNI), a beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor; Patients initiating vericiguat treatment as part of optimization of heart failure therapy according to routine clinical practice; Provision of written informed consent before any study-specific procedures.
Exclusion: Previous treatment with vericiguat; Failure or refusal to provide written informed consent; Cardiac surgery, coronary interventions, or mitral valve interventions performed before the scheduled follow-up reassessment; -; Age younger than 18 years; Pregnancy or breastfeeding; Involvement in the planning or conduct of the study, including study-site personnel.